Dalargin-Ellara

General characteristics. Structure:

Active agent: даларгин (тирозил-Д-аланил-глицил-фенилаланил-лейцил-аргинина diacetate) - 1 mg.

Pharmacological properties:

Pharmacodynamics. Substance of the peptide nature, synthetic hexapeptide, endogenous antagonist of opioid receptors. Suppresses proteolysis and promotes healing of stomach ulcers and a duodenum. Has moderate anti-secretory activity, reduces acidity of a gastric juice. Suppresses external secretion of a pancreas in response to various irritants (food, secretin, etc.).

At damage of a pancreas in an eksperiyenta it is shown that drug reduces a giperfermentemiya, limits the centers of a necrosis and promotes their substitution by full-fledged fabric, weakens synthesis of proteolytic enzymes a pancreas. Possesses insignificant hypotensive action.

Pharmacokinetics. Researches of pharmacokinetics were not conducted.

Indications to use:

- a peptic ulcer of a stomach in an aggravation phase;

- a duodenum ulcer in an aggravation phase;

- acute pancreatitis, pancreatonecrosis.

Route of administration and doses:

Intramusculary or intravenously. Just before use contents of an ampoule dissolve in 1 ml 0,9% of solution of sodium of chloride for injections. At aggravations of a peptic ulcer of a stomach and duodenum a single dose of 1 mg. The highest daily - 5 mg. Course of treatment 3-4 weeks. The general dose on a course of treatment makes 30-50 mg.

At acute pancreatitis the drug is administered intravenously in a dose of 2 mg, then on 5 mg of 1 - 2 time a day. Course of treatment of 4-6 days.

At a pancreatonecrosis enter intravenously 5 mg 3-4 times a day (in 6 - 8 hours). Course of treatment from 2 to 6 days.

Features of use:

Use of drug at pregnancy, during breastfeeding, children contraindicated. Data on features of use by the adults having chronic diseases no.

Side effects:

Allergic reactions, lowering of arterial pressure.

Interaction with other medicines:

Data are absent.

Contraindications:

Hypersensitivity, arterial hypotension, acute infectious processes, pregnancy, breastfeeding, children's age.

Overdose:

Now about cases of overdose of drug it was not reported.

Storage conditions:

To store in the place protected from light at a temperature not above 20 °C. 

To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Lyophilisate for preparation of solution for intravenous and intramuscular administration.

In ampoules of neutral about 1 mg flowed. On 5 ampoules in a blister strip packaging from a PVC film. 1 or 2 blister strip packagings with the application instruction and the ampoule scarificator in a cardboard pack. 5 or 10 ampoules together with the application instruction and the ampoule scarificator in a cardboard pack with a corrugated insert.

When using ampoules with a point or a ring of a break the scarificator ampoule does not invest in a pack.